Praxis Precision Medicines, Inc. announced positive topline results from its EMBOLD study of relutrigine for treating SCN2A and SCN8A developmental and epileptic encephalopathy in patients aged 2-18, showing a 46% reduction in motor seizures and 75% median reduction in the long-term extension, with no serious adverse events reported.